Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely reflects acyclovir labeling for indications, dosing, and safety events, but numerous valacyclovir-specific claims are unsupported by the provided label. There are a few dosing-duration fine points that diverge (e.g., shingles duration). Overall, the alignment is moderate with meaningful omissions related to valacyclovir and non-labeled details.
Category Scores
Accurate Statements
Acyclovir reduces outbreak duration, pain, and viral shedding in genital herpes, shingles, and chickenpox.
Genital herpes: duration of acute infection and lesion healing; Shingles: reduced duration of viral shedding and lesion formation; Chickenpox: shortened time to healing.
Oral bioavailability of acyclovir is 10-20%.
PHARMACOKINETICS: Average oral bioavailability 10% to 20%.
Typical dosing frequency for genital herpes: Acyclovir five times daily.
Genital herpes regimen: 200 mg every 4 hours, five times daily for 10 days.
Shingles treatment duration for acyclovir is 7-10 days with 800 mg five times daily.
Shingles: 800 mg five times daily for 7-10 days.
Intravenous acyclovir is indicated for varicella-zoster infections in immunocompromised patients.
IV acyclovir is indicated for varicella-zoster infections in immunocompromised patients.
There was no effect of food on absorption of acyclovir (oral suspension may be given with or without food).
There was no effect of food on the absorption; oral suspension may be administered with or without food.
In renal impairment, dose modification is recommended (dosage adjustment for renal impairment).
Special Populations: Adults with impaired renal function; Table 3 shows adjusted regimens.
Acyclovir oral suspension bioequivalence: acyclovir oral suspension is bioequivalent to capsules; 1 acyclovir 800-mg tablet is bioequivalent to 4 acyclovir 200-mg capsules.
Bioequivalence of dosage forms: Suspension vs capsules; tablet vs capsules.
Adults greater than 50 years of age showed greater benefit with treatment for herpes zoster.
Clinical trials note greater benefit in adults >50 years.
Unsupported Statements
Valacyclovir is a prodrug of acyclovir.
Label sections provided discuss acyclovir but do not mention valacyclovir as a prodrug.
Valacyclovir is converted to acyclovir after absorption.
No valacyclovir pharmacokinetics or conversion data are described in the provided sections.
Valacyclovir delivers the same active drug as acyclovir.
Label does not discuss valacyclovir delivering acyclovir as the active moiety.
Valacyclovir has better bioavailability—about 55% vs 10-20% for oral acyclovir.
Valacyclovir pharmacokinetics are not provided in the labeled sections.
Typical dosing frequency for genital herpes: Valacyclovir twice daily.
Valacyclovir dosing for genital herpes is not described in the provided sections.
Intravenous valacyclovir for severe cases like herpes encephalitis.
The label discusses IV acyclovir for varicella-zoster in immunocompromised patients; no valacyclovir data.
Valacyclovir is mainly oral.
Valacyclovir formulations and route predominance are not described in the provided sections.
Oral bioavailability of valacyclovir is ~55%.
Valacyclovir pharmacokinetics are not provided in the label.
Shingles treatment duration for acyclovir: 5-10 days (instead of 7-10).
Label specifies 7-10 days for shingles with 800 mg qid; 5-10 days is not exact.
Acyclovir reduces viral shedding in genital herpes, shingles, and cold sores.
Label documents reductions in duration and healing for genital herpes and shingles; 'cold sores' (non-specified) is not explicitly described in the provided sections.
Valacyclovir reduces outbreak duration, pain, and viral shedding in genital herpes, shingles, and cold sores.
Valacyclovir efficacy data are not provided in the labeled sections.
Valacyclovir's higher plasma levels lead to faster lesion healing by ~1-2 days.
No valacyclovir pharmacodynamics or lesion-healing data are provided in the labeled sections.
Valacyclovir provides better suppression in recurrent cases.
No valacyclovir-specific suppression data in the label.
Studies show similar cure rates, but valacyclovir improves patient adherence due to convenience.
No comparative adherence data for valacyclovir in the label.
No head-to-head trials show one vastly superior; choice depends on severity and compliance.
No label-based head-to-head conclusion provided.
Generic acyclovir costs $10-30 for a 5-day herpes course.
Pharmacoeconomic pricing is not in the label.
Valacyclovir generics run $20-60.
Pricing is not in the label.
Valacyclovir's branded Valtrex patent expired in 2009, with generics since.
Patent status not provided in the label.
Acyclovir, off-patent since the 1990s, is cheaper overall.
Patent/pricing history not provided in the label.
Check DrugPatentWatch.com for formulation-specific patents.
External patent-tracking resources are not discussed in the label.
Use acyclovir for cost-sensitive cases, topical needs, or IV therapy in hospitals.
Topical use is not explicitly described in the provided sections; IV use is mentioned but specific topical indication is not.
Contradictions
Low
AI Statement
Shingles treatment duration for acyclovir: 5-10 days, 800 mg five times daily.
Label Reference
DOSAGE AND ADMINISTRATION
Important Omissions
Valacyclovir-specific pharmacology, formulations, dosing regimens, and efficacy data.
Importance:
Moderate
Administration instructions specific to valacyclovir; route, dosing, and common forms.
Importance:
Moderate
State-of-the-art or brand-specific patent/pricing details and external references.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label-supported adverse events and renal/dosing considerations are within expected ranges; however, several valacyclovir-specific safety assertions are not supported by the provided label text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Valacyclovir-related claims largely unsupported by the provided label; several dosing/administration points for valacyclovir are not present.
Suggested Improvement
Limit claims to label-supported information; avoid valacyclovir-specific assertions unless supported by the label. If discussing valacyclovir, cite pharmacokinetic/pharmacology data from labeled sections (or clearly mark as outside the provided label).